GlassScriptPhysician profile
Jack W Carey
NPI 1265657951
$859.19
in general payments reported to CMS, 2019-2025
14 companies · $53.84 in 2025
The $53.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $43.64 · 2022: $118 · 2023: $122 · 2024: $204 · 2025: $53.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $150.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $97.33 | 2019-2024 | Xarelto |
| Abbvie INC. | $92.96 | 2022-2025 | Dalvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.87 | 2019-2024 | Xifaxan |
| Pfizer INC. | $86.93 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $83.45 | 2022-2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $61.20 | 2019-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.44 | 2019-2025 | Lifevest |
| Portola Pharmaceuticals, LLC | $41.95 | 2019 | |
| Abiomed | $37.66 | 2024 | Impella |
| La Jolla Pharmaceutical Company | $18.91 | 2024 | Xerava |
| Cumberland Pharmaceuticals, INC. | $18.34 | 2019 | |
| Chiesi USA, INC. | $13.48 | 2025 | Cleviprex, Kengreal |
| Irhythm Technologies, INC. | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.